Company
Headquarters: Beijing, China
Employees: 992
CN¥32.64 Billion
CNY as of July 1, 2025
US$4.56 Billion
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $309.91 B |
| Vertex Pharmaceuticals Incorporated | $117.36 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $59.14 B |
| Marinomed Biotech AG | $58.56 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Sinocelltech Group Limited, a biotech company, focuses on the development of technologies for the development and manufacturing of recombinant proteins, monoclonal antibodies, and vaccines in China. The company is based in Beijing, China.
| Last Financial Reports Date | March 31, 2025 |
| Revenue TTM | CN¥2.42 B |
| EBITDA | CN¥383.3 M |
| Gross Profit TTM | CN¥2.29 B |
| Profit Margin | 4.20% |
| Operating Margin | 10.69% |
| Quarterly Revenue Growth | -15.10% |
Sinocelltech Group Ltd has the following listings and related stock indices.
Stock: SSE: 688520 wb_incandescent